Options
Weber, Martin S.
Loading...
Preferred name
Weber, Martin S.
Official Name
Weber, Martin S.
Alternative Name
Weber, M. S.
Weber, Martin
Weber, M.
Main Affiliation
Now showing 1 - 4 of 4
2020Journal Article [["dc.bibliographiccitation.firstpage","e698"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Neurology - Neuroimmunology Neuroinflammation"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Häusler, Darius"],["dc.contributor.author","Hajiyeva, Zivar"],["dc.contributor.author","Traub, Jan W."],["dc.contributor.author","Zamvil, Scott S."],["dc.contributor.author","Lalive, Patrice H."],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Weber, Martin S."],["dc.date.accessioned","2021-04-14T08:26:30Z"],["dc.date.available","2021-04-14T08:26:30Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1212/NXI.0000000000000698"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81971"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2332-7812"],["dc.title","Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]Details DOI2019Journal Article [["dc.bibliographiccitation.firstpage","e10"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Brain: A Journal of Neurology"],["dc.bibliographiccitation.lastpage","e10"],["dc.bibliographiccitation.volume","143"],["dc.contributor.author","Häusler, Darius"],["dc.contributor.author","Torke, Sebastian"],["dc.contributor.author","Peelen, Evelyn"],["dc.contributor.author","Bertsch, Thomas"],["dc.contributor.author","Weber, Matthias"],["dc.contributor.author","Heilmann, Marcus"],["dc.contributor.author","Djukic, Marija"],["dc.contributor.author","Nau, Roland"],["dc.contributor.author","Larochelle, Catherine"],["dc.contributor.author","Zamvil, Scott S"],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Weber, Martin S"],["dc.date.accessioned","2021-04-14T08:27:32Z"],["dc.date.available","2021-04-14T08:27:32Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1093/brain/awz389"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82322"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1460-2156"],["dc.relation.issn","0006-8950"],["dc.title","Reply: Neither human nor mouse is hypercalcaemic with 250 nmol/l 25-hydroxyvitamin D"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]Details DOI2020Journal Article [["dc.bibliographiccitation.firstpage","535"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Acta Neuropathologica"],["dc.bibliographiccitation.lastpage","548"],["dc.bibliographiccitation.volume","140"],["dc.contributor.author","Torke, Sebastian"],["dc.contributor.author","Pretzsch, Roxanne"],["dc.contributor.author","Häusler, Darius"],["dc.contributor.author","Haselmayer, Philipp"],["dc.contributor.author","Grenningloh, Roland"],["dc.contributor.author","Boschert, Ursula"],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Weber, Martin S."],["dc.date.accessioned","2021-04-14T08:24:46Z"],["dc.date.available","2021-04-14T08:24:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00401-020-02204-z"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81418"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1432-0533"],["dc.relation.issn","0001-6322"],["dc.title","Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]Details DOI2018Journal Article [["dc.bibliographiccitation.firstpage","9773"],["dc.bibliographiccitation.issue","39"],["dc.bibliographiccitation.journal","Proceedings of the National Academy of Sciences"],["dc.bibliographiccitation.lastpage","9778"],["dc.bibliographiccitation.volume","115"],["dc.contributor.author","Häusler, Darius"],["dc.contributor.author","Häusser-Kinzel, Silke"],["dc.contributor.author","Feldmann, Linda"],["dc.contributor.author","Torke, Sebastian"],["dc.contributor.author","Lepennetier, Gildas"],["dc.contributor.author","Bernard, Claude C. A."],["dc.contributor.author","Zamvil, Scott S."],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Lehmann-Horn, Klaus"],["dc.contributor.author","Weber, Martin S."],["dc.date.accessioned","2021-06-01T10:51:05Z"],["dc.date.available","2021-06-01T10:51:05Z"],["dc.date.issued","2018"],["dc.description.abstract","The anti-CD20 antibody ocrelizumab, approved for treatment of multiple sclerosis, leads to rapid elimination of B cells from the blood. The extent of B cell depletion and kinetics of their recovery in different immune compartments is largely unknown. Here, we studied how anti-CD20 treatment influences B cells in bone marrow, blood, lymph nodes, and spleen in models of experimental autoimmune encephalomyelitis (EAE). Anti-CD20 reduced mature B cells in all compartments examined, although a subpopulation of antigen-experienced B cells persisted in splenic follicles. Upon treatment cessation, CD20 + B cells simultaneously repopulated in bone marrow and spleen before their reappearance in blood. In EAE induced by native myelin oligodendrocyte glycoprotein (MOG), a model in which B cells are activated, B cell recovery was characterized by expansion of mature, differentiated cells containing a high frequency of myelin-reactive B cells with restricted B cell receptor gene diversity. Those B cells served as efficient antigen-presenting cells (APCs) for activation of myelin-specific T cells. In MOG peptide-induced EAE, a purely T cell-mediated model that does not require B cells, in contrast, reconstituting B cells exhibited a naive phenotype without efficient APC capacity. Our results demonstrate that distinct subpopulations of B cells differ in their sensitivity to anti-CD20 treatment and suggest that differentiated B cells persisting in secondary lymphoid organs contribute to the recovering B cell pool."],["dc.identifier.doi","10.1073/pnas.1810470115"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86889"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1091-6490"],["dc.relation.issn","0027-8424"],["dc.title","Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]Details DOI